Abstract

Both neuropsychiatric disorders and malignancies of central nervous system (CNS) represent a significant health burden and life-threatening diseases worldwide. Radiotracer-based neuroimaging is an attractive tool that permits the in vivo detection and characterization of metabolic and molecular processes which are fundamental elements for brain function, and improves the theranostics of brain diseases and disorders.

In this review, we outlined the new development of molecular imaging probes for dopamine and serotonin systems in neuropsychiatry and boron neutron capture therapy (BNCT) for brain tumors in neuro-oncology with positron emission tomography (PET) and single-photon emission computed tomography (SPECT).

Keywords: Boron neutron capture therapy, dopamine, molecular imaging, positron emission tomography, serotonin, singlephoton emission computed tomography.